# OnCo record paper-imspire150-lancet-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-imspire150-lancet-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-imspire150-lancet-2020" ;
  schema:name "Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial"@en ;
  schema:description "Published report from the IMspire150 trial registered as NCT02908672, in The Lancet (2020), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-imspire150-lancet-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(20)30934-x>, <https://pubmed.ncbi.nlm.nih.gov/32534646/>, <https://europepmc.org/article/MED/32534646>, <https://clinicaltrials.gov/study/NCT02908672> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(20)30934-x> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Gutzmer R, Stroyakovskiy D, Gogas H, et al." ;
  onco:trials <https://onco.cc/trials/imspire150/> ;
  onco:journals <https://onco.cc/journals/lancet/> .